Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label randomized study of elisidepsin (IRVALEC) in advanced gastroesophageal cancers
2010-020325-40Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jul 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elisidepsin in esophageal cancer, esophagogastric junction cancer and gastric cancer (GC), sponsored by PharmaMar. Started Jul 2010; status: completed.
02
Drugs
elisidepsin
03
Conditions
esophageal canceresophagogastric junction cancergastric cancer (GC)
Beyond the preview
Go deeper on 2010-020325-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020325-40.